Skip to content
10-Q

Quarterly Report

Flexion Therapeutics, Inc.

0001564590-20-050458

← back to feed
Filed
Nov 4, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Nov 1, 2020 49.32M sh
Long Term Debt Q3 2020 · Sep 30, 2020 $48.47M
Long Term Debt Q3 2020 · Dec 31, 2019 $40.18M
Short Term Debt Q3 2020 · Sep 30, 2020 $12.22M
Cash And Equivalents Q3 2020 · Sep 30, 2020 $128.64M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $82.25M
Current Liabilities Q3 2020 · Sep 30, 2020 $50.88M
Current Liabilities Q3 2020 · Dec 31, 2019 $36.22M
Total Liabilities Q3 2020 · Sep 30, 2020 $266.46M
Total Liabilities Q3 2020 · Dec 31, 2019 $237.67M
Current Assets Q3 2020 · Sep 30, 2020 $237.07M
Current Assets Q3 2020 · Dec 31, 2019 $195.68M
Total Assets Q3 2020 · Sep 30, 2020 $263.37M
Total Assets Q3 2020 · Dec 31, 2019 $217.56M
Capex Q3 2020 · Sep 30, 2019 $1.12M
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$109.82M
Stockholders Equity Q3 2020 · Sep 30, 2019 $7.17M
Stockholders Equity Q3 2020 · Jun 30, 2019 $41.47M
Stockholders Equity Q3 2020 · Mar 31, 2019 $72.58M
Stockholders Equity Q3 2020 · Dec 31, 2018 $110.08M
Sga Expense Q3 2020 · Sep 30, 2019 $32.14M
Sga Expense Q3 2020 · Sep 30, 2019 $97.46M
Rd Expense Q3 2020 · Sep 30, 2019 $20.94M
Rd Expense Q3 2020 · Sep 30, 2019 $52.49M
Net Income Q3 2020 · Sep 30, 2019 −$38.23M
Net Income Q3 2020 · Sep 30, 2019 −$116.26M
Net Income Q3 2020 · Jun 30, 2019 −$36.49M
Net Income Q3 2020 · Mar 31, 2019 −$41.54M
Operating Income Q3 2020 · Sep 30, 2019 −$34.16M
Operating Income Q3 2020 · Sep 30, 2019 −$106.68M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $2.87M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $6.03M
Revenue Q3 2020 · Sep 30, 2019 $21.79M
Revenue Q3 2020 · Sep 30, 2019 $49.3M